{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:32:21Z","timestamp":1782739941035,"version":"3.54.5"},"reference-count":40,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>There is a lack of real\u2010world data in Asian populations for brigatinib, a next\u2010generation anaplastic lymphoma kinase (ALK) inhibitor for patients with non\u2010small cell lung cancer (NSCLC). This study analysed real\u2010world outcomes and dosing patterns for brigatinib in patients with crizotinib\u2010refractory <jats:italic>ALK<\/jats:italic>+ NSCLC in South Korea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective, non\u2010interventional, cohort study used South Korean Health Insurance and Review Assessment claims data for adults with <jats:italic>ALK+<\/jats:italic> NSCLC who initiated brigatinib between 19 April 2019 and 31 March 2021 after receiving prior crizotinib. Patients' characteristics, time to discontinuation (TTD), time to dose reduction, overall survival (OS) and treatment adherence were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 174 patients (56.9% male; 27.0% with a history of brain metastases). Median duration of prior crizotinib was 17 (range 0.3\u201348) months. Median follow\u2010up after brigatinib initiation was 18 (range 0\u201334) months. Overall, 88.5% of patients received full\u2010dose brigatinib (180\u2009mg\/day) and 93.1% of patients were adherent (proportion of days covered \u22650.8). The median TTD was 24.9\u2009months (95% CI 15.2\u2013not reached). The probability of continuing treatment was 63.2% at 1\u2009year and 51.5% at 2\u2009years. The probability of continuing at full or peak dose was 79.7% at 1\u2009year and 75.6% at 2\u2009years. Median OS was not reached. The 2\u2010year OS rate was 68.7%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this first nationwide retrospective study using national insurance claim data, brigatinib demonstrated real\u2010world clinical benefit as second\u2010line treatment after prior crizotinib in <jats:italic>ALK<\/jats:italic>+ NSCLC patients in South Korea.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.70030","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T04:39:03Z","timestamp":1721363943000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real\u2010world evidence of brigatinib as second\u2010line treatment after crizotinib for <i>ALK<\/i>+ non\u2010small cell lung cancer using South Korean claims data (K\u2010<scp>AREAL<\/scp>)"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6173-2748","authenticated-orcid":false,"given":"Jeong Eun","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Pulmonology, Department of Internal Medicine, College of Medicine Chungnam National University  Daejeon Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hyun","family":"Nam","sequence":"additional","affiliation":[{"name":"Division of Big Data Science Korea University  Sejong Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hong","family":"Kwon","sequence":"additional","affiliation":[{"name":"School of Pharmacy Sungkyunkwan University  Suwon Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Kyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals Korea Co., Ltd.  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Min","family":"Ha","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals Korea Co., Ltd.  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.447"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2011.09.001"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0168"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00004-0"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30050384"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2016.08.012"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.863461"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0569"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100385"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.08.010"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.035"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac116"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.05.017"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0747"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0849"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.461"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.906211"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.030"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1005626"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.858279"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100612"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.21.1740"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01300-9"},{"issue":"7","key":"e_1_2_12_26_1","first-page":"723","article-title":"Management strategies for adverse events associated with EGFR TKIs in non\u2010small cell lung cancer","volume":"7","author":"Vogel WH","year":"2016","journal-title":"J Adv Pract Oncol"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15050645"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810171"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214886"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704795"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz060"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.493"},{"key":"e_1_2_12_33_1","unstructured":"Brigatinib prescribing information. 2022. Accessed November 28 2023.https:\/\/www.alunbrig.com\/hcp\/sites\/default\/files\/2022\u201009\/pi.pdf"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.01.020"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103847"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-060782"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.21310"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.07.008"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2022.11.2.103"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08082-2"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55150-6"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T22:45:36Z","timestamp":1744929936000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":40,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/cam4.70030"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70030","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70030"}}